Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24061116 | 0.90 | MC4R (0.57) | MC4RALDH1A1KDM4EMAPTHTT | |
| SCHEMBL6726868 | 0.90 | ALDH1A1 (0.55) | MC4RALDH1A1KDM4EMAPTHTT | |
| SCHEMBL13535291 | 0.89 | MC4R (0.74) | MC4RALDH1A1KDM4EMAPTHRH3 | |
| SCHEMBL15829984 | 0.86 | ALDH1A1 (0.62) | ALDH1A1KDM4EMAPTHTTLMNA | |
| SCHEMBL12981 | 0.85 | HRH3 (0.69) | ALDH1A1KDM4EMAPTHTTHRH3 | |
| SCHEMBL31546411 | 0.85 | HRH3 (0.69) | ALDH1A1KDM4EMAPTHTTHRH3 | |
| SCHEMBL16220681 | 0.85 | ALDH1A1 (0.63) | ALDH1A1KDM4EMAPTHTTHRH3 | |
| SCHEMBL15829997 | 0.85 | ALDH1A1 (0.59) | ALDH1A1KDM4EMAPTHTTHRH3 | |
| SCHEMBL9094324 | 0.85 | ALDH1A1 (0.63) | ALDH1A1KDM4EMAPTHTTHRH3 | |
| SCHEMBL12880000 | 0.84 | HRH3 (0.78) | ALDH1A1KDM4EMAPTHRH3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239629-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE CDK2 | Plexium, Inc. (US) | 2023-12-14 | — | — | WO | disclosed |
| EP-4219465-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3498701-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2023-02-22 | — | — | EP | disclosed |
| WO-2022263548-A1 | 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS | LEAD DISCOVERY CENTER GMBH (DE) | 2022-12-22 | — | — | WO | disclosed |
| EP-4104901-A1 | 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS | Lead Discovery Center GmbH (DE) | 2022-12-21 | — | — | EP | disclosed |
| EP-3708169-A1 | 2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-SULFONAMIDE DERIVATIVES HAVING AN ANTICANCER ACTIVITY | Agios Pharmaceuticals, Inc. (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3241554-B1 | QUINOLINE-8-SULFONAMIDE DERIVATIVES HAVING AN ANTICANCER ACTIVITY | AGIOS PHARMACEUTICALS INC (US) | 2020-01-29 | — | — | EP | disclosed |
| EP-2935247-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2019-08-28 | — | — | EP | disclosed |
| EP-3498701-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2019-06-19 | — | — | EP | disclosed |
| EP-2935243-B1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | EPIZYME INC (US) | 2018-03-14 | — | — | EP | disclosed |
| WO-2007131072-A2 | HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE | ANACOR PHARMACEUTICALS, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| US-20070232622-A1 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232622-A1 | Small molecule toll-like receptor (TLR) antagonists | COLEY PHARMACEUTICAL GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20070027166-A1 | Pyrazolo pyrimidines useful as aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232622-A1 | Small molecule toll-like receptor (TLR) antagonists | TLR3, TLR8, TLR7 | MC4R 1380/4885ALDH1A1 4582/4885KDM4E 1460/4885 |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | TP53, BRCA1, KLK3 | MC4R 3910/4885ALDH1A1 1270/4885KDM4E 3368/4885 |
| US-20070027166-A1 | Pyrazolo pyrimidines useful as aurora kinase inhibitors | AURKA, AURKB, AURKC | MC4R 4416/4885ALDH1A1 3764/4885KDM4E 951/4885 |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, HTR3C | MC4R 465/4885ALDH1A1 904/4885KDM4E 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.